Member Info for violindog

Yes GF.....three...🤣

Drac...as long as the deal goes ahead 🤞

Thanks for all of your thoughts. I guess with Redmile as our largest instutional holder ...they regarded the science over the penny share status.

It is completely illogical, but I "feel" a higher SP post consolidation would lift the status of Scancell and attract a wider investor pool.

I know its the market capital that's the important figure ... but we are almost at an eye-watering billion shares .

Hi Guys ...i know that they are two very different companies and pipelines and Scancell has never had issues raising or attracting capital ...indeed the last retail offer was increased due to demand. That said, I did find the RNS from Hemo

re the penny share status interesting. Would Scancell ever consider a consolidation ...would it be of any benefit ?

I don't want to get into any debate about Hemo Vs Scancell etc etc ...just interested if a higher SP via consolidation may attract more intuitional demand as per the reasons in Hemos RNS ? Would it help ?

"The Company is at a pivotal stage in its progress and has received injections of equity capital to support its clinical trial activities. The Directors consider, having received feedback from some potential funders, that the "penny share" perception of the Company's shares deters most institutional and professional investors from participating in capital raises which the Company undertakes. This is relevant to both UK institutions and US-based life-sciences oriented institutional investors and potential partners. As it enters clinical trials for HEMO-CAR-T and resumes development of its other product candidates, it will potentially seek further funding and believes that a higher share price following a reorganised share capital is likely to open up the pool of such potential institutional and professional investors who will, it believes be more likely to subscribe for new equity in future fundraises."

Did a 1.8 million trade just get printed? Buy or sell?

HH... you are correct. No matter how brilliant the results are... funding is the millstone, once sorted hopefully it will act as a life vest. Unless we get an offer accepted by Redmile.

New management...new chapter 🤞

Early days, but the CEO should signal the market and investors... and buy some shares !

Dr Phil L'Huillier , Chief Executive Officer (CEO)

I wonder if he will buy any shares on the open market?? ....or rely on options once granted.

Well, Hires Phil L'Huillier chief executive officer has had a good introduction into how Scancell’s RNS s are received even if excellent news. He has his work cut out !!

Chester18,

From today's RNS " It is anticipated that all cohort 3 patients will reach week 25 during H2 2025. This will allow us to select the best vaccine for our planned phase 2/3 randomised, adapted registration trial."

So H2 before a decision is made re the registration trial, Scib or iScib. H2 is a wide target and as a result when will the trial reasonably commence ? Alot of work can be done prior to any decision and by H2 funding will hopefully be sorted .

We will see how January's decision goes and if we get any more news on Moditope... but hopefully expectation of funding and trial sucess will build the SP

Moon, I agree with your post, let the implications sink in, and I expect the SP will increase gradually.

Although today's RNS doesn't give the complete road map at least we know Scib works and I'm confident that a pharma on reviewing both these results in combination with the original trial will offer a deal.

Johnny....well , I hope that they start banging the drum . Any pharma potentially interested will be well aware of todays RNS. I would be disappointed if Scancell had to go touting for potential deals at this stage. Surely the very original SCIB trial combined with today's data should be enough to trigger a deal without waiting for H2 25 results 🤞

CrustyPete, re funding etc - this is from Trinity :

Trinity Delta view: Data from the SCOPE study are reassuring and pave the way for the planned randomised adaptive Phase II/III trial. Assuming continuing positive results at week 25 for both Cohorts 1 and 3, investor attention will understandably centre on the funding of this potentially pivotal study. Our forecast cash runway extends to Q325, beyond these SCIB1/iSCIB1+ milestones and Modi-1 data in H125; however, our cash assumptions do not include any potential licensing deals for the GlyMab and/or AvidiMab antibody platforms. We note that the seven-month evaluation deal with an unnamed partner could result in option exercise in Q125, which could trigger a similar upfront payment and licence deal to that struck with Genmab in October 2022.

So....£5 odd million if the unknown company take the licence after the evaluation - will will know the result shortly - and with a cash runaway until Q325, if there are no deals Scancell would need to rattle the tin at least a couple of months prior to Q325. So its all down to the managements ability to do deals . Funding as always the millstone around Scannell's neck.

So ..Trinity maintain 33p value and Panmure at 23.3 p and despite brilliant results the market takes us down to 15.5p.

Its always funding and delays that keeps the lid on Scancell's SP despite the impressive results. Such a different story if we were on the Nasdaq.

SP reaction.....unbelievable... and this is why we should be on the Nasdaq

Hi Maivoce, yes hopefully an exciting week...we must be so close now ...

The vaccine issue and the politics around them will now be etched into the history of the World. Everyone will have an opinion/ conspiracy, some will speak from a well researched view point and others follow whatever media feed suits their political stance.

Personally, I have no objection to vaccines but there must be open and honest discussion / disclosure about any potential harms. How many of us readily take drugs without reading the accompanying leaflet and the horrors they contain if you are the unlucky 1: 100 1: 1000 etc etc ... and even if you read them does it help the average person make an informed decision.

The pharm lobbying will protect the "industry". When faced with cancer, I think 99% of patients would take a cancer vaccine when faced with the prospect of death.

C11, a mixed bag...the US food chain has far more chemicals allowed compared to European standards. Is it too much to ask patents to ensure children brush their teeth effectively? Or do we go for the easy option of adding fluoride to everyone's water? Look at the pain med scandals in the US ...pushed by pharma...simple cheap remedies squashed by pharma pushing expensive drugs and pharma lobbying of Congress with their brown envelopes.

So a mixed bag....yes.. he has some illogical opinions but there is alot wrong in the system .

Merck & Co. is paying $588 million upfront to defend its Keytruda kingdom. The outlay, plus up to $2.7 billion in milestones, has secured Merck global rights to LaNova Medicines’ PD-1xVEGF bispecific antibody.

https://www.fiercebiotech.com/biotech/merck-pays-588m-bispecific-defend-keytrudas-kingdom-emerging-threat